Carl Zeiss Meditec (XTRA:AFX) Reports Lower Nine Month Earnings, Is The Stock Now Cheap?
Earnings results put Carl Zeiss Meditec stock in focus
Carl Zeiss Meditec (XTRA:AFX) has drawn fresh attention after reporting nine month earnings to June 30, 2026, with both sales and net income lower than the prior period, prompting investors to reassess the stock.
See our latest analysis for Carl Zeiss Meditec.
Following the earnings release on 5 August 2026, Carl Zeiss Meditec’s share price of €29.30 reflects pressure in the short term, with the stock down 3.2% over one day but still showing a 13.9% 90 day share price return against a much weaker 1 year total shareholder return of 30.8%.
If this earnings reaction has you reassessing healthcare exposure, it can be useful to see how other medical technology and life science companies linked to artificial intelligence are trading right now through the 128 healthcare AI stocks
Carl Zeiss Meditec now trades well below one estimate of intrinsic value, yet only slightly above the average analyst target after the earnings setback. Is the discount a genuine opportunity, or is the market rightly cautious?
Most Popular Narrative: 2.3% Overvalued
The most followed narrative currently points to a fair value of €28.63 for Carl Zeiss Meditec, which sits slightly below the latest close at €29.30.
The analysts have a consensus price target of €28.63 for Carl Zeiss Meditec based on their expectations of its future earnings growth, profit margins and other risk factors.
Want to see what sits beneath that fair value line? The narrative leans on firm revenue assumptions, a step up in margins, and a future earnings multiple that may surprise you.
Result: Fair Value of €28.63 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Carl Zeiss Meditec still faces pressure from weaker organic sales and a lower EBITA margin, which could challenge the earnings path that underpins this fair value view.
Find out about the key risks to this Carl Zeiss Meditec narrative.
Another View on Carl Zeiss Meditec’s value
While the analyst narrative points to Carl Zeiss Meditec trading about 2.3% above its €28.63 fair value estimate, the SWS DCF model indicates a very different picture. On that measure, the stock trades at €29.30 against a future cash flow value of €80.63, which screens as heavily undervalued. Which lens do you trust more for your own work up?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
The mixed signals around Carl Zeiss Meditec can feel unclear, so it makes sense to act while the details are fresh and test the numbers yourself. You can start with the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Carl Zeiss Meditec?
If Carl Zeiss Meditec has sharpened your focus, now is the moment to expand your watchlist using structured stock ideas instead of chasing headlines.
- Target potential value opportunities by scanning 253 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their underlying strength.
- Prioritise resilience by reviewing 299 resilient stocks with low risk scores that score well on financial health and business stability, so short term noise is less likely to derail your plan.
- Get ahead of the crowd by studying a screener containing 550 high quality undiscovered gems before they sit firmly on everyone else's radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com